Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
about
Visceral Leishmaniasis and HIV coinfection in East AfricaDecentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature reviewOne Health Approach Prospect for Integrated Control and Elimination of Visceral Leishmaniasis in Ethiopia: A Narrative Review ArticleRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisPredictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic reviewTreatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, IndiaHigh parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in EthiopiaA screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia.Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.Visceral leishmaniasis as an AIDS defining condition: towards consistency across WHO guidelinesVisceral leishmaniasis in the Indian subcontinent: modelling epidemiology and controlVisceral leishmaniasis and HIV coinfection: time for concerted action.Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent.Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guideImpact of the use of a rapid diagnostic test for visceral leishmaniasis on clinical practice in Ethiopia: a retrospective study.Eco-epidemiology of visceral leishmaniasis in Ethiopia.Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisPrevalence of malnutrition and associated risk factors among adult visceral leishmaniasis patients in Northwest Ethiopia: a cross sectional study.Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies.Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in EthiopHIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil.Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.Genome wide comparison of Ethiopian Leishmania donovani strains reveals differences potentially related to parasite survival.Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.Challenges in HIV and visceral Leishmania co-infection: future research directions.Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from EthiopiaAnalysis of genetic polymorphisms and tropism in East African Leishmania donovani by Amplified Fragment Length Polymorphism and kDNA minicircle sequencing
P2860
Q24290704-44344B4A-8CE3-4669-8912-A134E8B154C2Q26739026-65EF7B32-1719-4630-9266-AC0FBDC5B0AFQ26751878-527C7A4E-C5FD-4251-8AB2-BD9DFC85F03EQ27011766-E7E69C69-4956-4628-9B12-D2F80E968ADCQ28478476-325C3E1B-494E-4F2A-BA85-AC5684981095Q28484459-43487623-3486-4964-8EC5-A1233353D61DQ28539053-631B338B-635A-4C9B-A518-CFBBA083B921Q28541690-8B827DA4-DEDF-4863-B428-52CCEDA8F3BAQ30275257-818E366C-7873-4C03-B9B7-3AC3D7BA2C66Q33660792-E7AF8040-6825-4766-AF12-C1323435FD78Q33764787-9C369787-92D7-4C8B-9A8A-31A135288BA8Q33915996-9215D541-AC17-4C0A-9702-06F16660EEB5Q34091527-0AEBC368-1C35-4E94-BF56-320816FF8B24Q34104507-E106B289-1167-485E-A46E-493A38C4F019Q34563619-DF34B723-A914-4213-89D1-FC5B0C8C4F47Q35151864-8269A732-2B38-45CB-81DD-E481F9AC89F9Q35156774-A36E6CBD-CA48-4E41-9E38-E8371D7378E8Q35160905-301802B8-DA18-463D-9ECF-558CCEA6A272Q35597666-F92C9467-5AEA-41A0-AD49-30A06161067EQ35863732-84397F37-F0C3-4854-B383-0E15BDD30E29Q36284391-28087243-B8BF-48C2-9AB6-66F5FB01242DQ36733559-30C84F42-DE69-4A4E-B1AE-0F775799141BQ36932080-C47B3044-0F48-4C14-B86D-43A027E1D18DQ37580608-D1012FA4-14B4-4BD6-ADF6-841372A3CBA7Q37689615-AD14CC25-573A-4887-900C-F662E7BC093AQ38514270-599D042D-256E-4782-9CC1-D5527352401CQ38973977-0F579208-0633-4075-831C-40E8152749F7Q39674196-390BB840-530F-43B1-9D8E-4CBA665629EAQ41787486-5957FB8D-DE3B-4906-8C2F-633CDA15620EQ42225232-3E839EDB-07FA-425E-97B4-2CD10F7263D9Q44895818-31743E4D-EB23-4067-9FCC-255BE9DFD20FQ45363637-22C71470-3336-48FA-9519-3C90681FFCF0Q48284181-211432AF-B30D-4726-B932-42681A5CD709Q50054022-A6616C87-ED31-481A-82F2-97B6712C4573Q51800025-E35F1FCE-5A50-41D6-8E28-42479410414FQ54219659-D3B6BCD2-0F8D-43B3-AA91-1E4A0C1E41C2Q55482423-A0C3F318-F27C-4881-A5E9-30E8193496DAQ57922379-1C30AFAF-AF3B-47F7-84AB-5FB1EE1D409EQ58701207-F1FBE971-D5B2-49B6-86C7-BCA061294677
P2860
Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical characteristics and t ...... fection in northwest Ethiopia.
@en
Clinical characteristics and t ...... fection in northwest Ethiopia.
@nl
type
label
Clinical characteristics and t ...... fection in northwest Ethiopia.
@en
Clinical characteristics and t ...... fection in northwest Ethiopia.
@nl
prefLabel
Clinical characteristics and t ...... fection in northwest Ethiopia.
@en
Clinical characteristics and t ...... fection in northwest Ethiopia.
@nl
P2093
P2860
P50
P921
P1476
Clinical characteristics and t ...... fection in northwest Ethiopia.
@en
P2093
Samuel Gebre-Silassie
Tewodros Tefera
Workagegnehu Hailu
Zewdu Hurissa
P2860
P304
P356
10.1111/J.1365-3156.2010.02550.X
P577
2010-05-14T00:00:00Z